James R. Berenson, MD
Founder and Chief Scientific Officer:
Dr. Berenson is the Founder and Principal of the Berenson Cancer Center, a unique multi-faceted business entity built around an established and integrated healthcare and biotech family of companies.
These consist of:
- Berenson Cancer Center:Â A prolific specialty practice in West Hollywood, CA focused on the treatment of patients with multiple myeloma and related malignancies and conditions. More than 600 patients are under his care.
- ONCOtherapeutics:Â A highly regarded targeted CRO leading clinical trials from phase I to IV in community and academic oncology sites throughout the United States.
- ONCOtracker: An emerging incubator biotech company developing innovative approaches for monitoring and treatment of patients with multiple myeloma, other B-cell malignancies, and related disorders.
He also is the Founder, President, and Medical and Scientific Director of the Institute for Myeloma & Bone Cancer Research (IMBCR): A mission‑driven 501(C)3 non-profit institute dedicated to the discovery of novel treatments for multiple myeloma and related conditions in a pre‑clinical in vitro and in vivo research laboratory and includes an extensive biobank with long-term clinical samples.
Dr. Berenson has authored nearly 300 peer-reviewed publications and contributed to multiple book chapters. He has served as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section and has been a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr. Berenson has served on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also serves on the Scientific Board of the International Waldenstroms’ Macroglobulinemia Foundation.
